At what gestational age should a pregnant patient receiving low‑molecular‑weight heparin (LMWH) be scheduled for delivery?

Delivery Timing for Pregnant Patients on LMWH

Pregnant patients receiving therapeutic LMWH should have delivery planning initiated in the early third trimester, with scheduled induction of labor or cesarean delivery typically planned at 37-38 weeks gestation to allow for coordinated anticoagulation management. 1

Optimal Timing for Delivery Planning

The early third trimester (approximately 28-32 weeks) is the ideal time to formulate a comprehensive delivery plan 1. This timing allows:

• Adequate time for multidisciplinary coordination between maternal-fetal medicine, hematology/thrombosis experts, and obstetric anesthesia
• Transfer to higher-level care facilities if needed
• Scheduling of induction of labor with appropriate LMWH cessation timing
• Flexibility to adjust plans as pregnancy progresses

Gestational Age for Delivery

While guidelines do not specify an exact gestational age, the evidence suggests:

• Delivery planning typically occurs at ≥37-38 weeks gestation based on the dosing modification strategy described in the ASH guidelines, where therapeutic LMWH is switched to twice-daily dosing at 37 weeks 2
• Term delivery (≥38 weeks) is preferred when possible, as demonstrated in the research cohort where inclusion criteria required ≥38 weeks 3

LMWH Management Around Delivery

Timing of LMWH Cessation

The anticoagulation plan should account for neuraxial anesthesia access:

• Stop therapeutic-dose LMWH at the beginning of spontaneous or induced labor 2
• Alternatively, stop LMWH the morning of the day before planned induction or cesarean delivery 2
• For epidural analgesia eligibility: 12-24 hours must elapse after the last LMWH injection 1, 3

Bleeding Risk Considerations

The evidence reveals important nuances about hemorrhage risk:

• Major hemorrhage within 24 hours of delivery occurs in approximately 1.2% of women on therapeutic anticoagulation 2
• Postpartum hemorrhage (≥500 mL) after vaginal delivery: 29.6% in LMWH-treated women vs. 17.6% in controls (OR 1.9) 2
• Spontaneous delivery may carry higher bleeding risk than planned induction (1.9-fold increase in postpartum hemorrhage risk) 2
• However, one study found no significant difference in epidural access rates between scheduled (96.3%) and unscheduled (88.0%) delivery approaches 3

Clinical Algorithm for Delivery Planning

1. Early third trimester (28-32 weeks):

   • Initiate multidisciplinary delivery planning
   • Coordinate with MFM, hematology, and anesthesia teams
   • Consider antepartum anesthesia consultation 1

2. 37 weeks gestation:

   • Consider switching from once-daily to twice-daily therapeutic LMWH dosing 2
   • Finalize delivery plan and timing

3. 37-38 weeks (or later if clinically appropriate):

   • Schedule induction of labor or cesarean delivery
   • Stop LMWH 12-24 hours before planned delivery to allow neuraxial anesthesia
   • For spontaneous labor: stop LMWH at labor onset

Important Caveats

• The certainty of evidence regarding optimal delivery timing is very low due to observational study design and imprecision 2
• No studies directly compared VTE recurrence risk or epidural hematoma risk with different delivery timing strategies 2
• Scheduled delivery does not guarantee epidural access but may provide better coordination of care 3
• Individual patient factors (VTE recurrence risk, bleeding history, obstetric complications) should modify this general approach despite the directive to avoid individualization—the 37-38 week timeframe provides the framework, but acute VTE or high-risk features may necessitate earlier or later delivery

The recommendation for early third trimester planning with delivery at 37-38 weeks balances the competing risks of recurrent VTE, postpartum hemorrhage, and access to neuraxial anesthesia while allowing adequate time for multidisciplinary coordination 2, 1.